Long-term evolution and predictive factors of mild inflammatory bowel disease

被引:11
|
作者
Reenaers, C. [1 ]
Pirard, C. [1 ]
Vankemseke, C. [1 ]
Latour, P. [1 ]
Belaiche, J. [1 ]
Louis, E. [1 ]
机构
[1] Univ Hosp Liege, Dept Gastroenterol, Liege, Belgium
关键词
Benign evolution; mild IBD; complication; predictive factor; CROHNS-DISEASE; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CLINICAL-COURSE; RISK; CLASSIFICATION; INFECTIONS; MORTALITY; COLECTOMY; BEHAVIOR;
D O I
10.3109/00365521.2015.1128965
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Crohn's disease (CD) and ulcerative colitis (UC) are potentially progressive diseases. Few data are available on the prevalence and the factors associated with mild inflammatory bowel diseases (IBD). Aim Our aim was to assess the natural history of mild CD and mild UC and to identify predictive factors of mild evolution over the long term. Methods Retrospective study of IBD patients registered in the database of the university hospital CHU of Liege, Belgium. Mild CD was defined as an inflammatory luminal disease (no stricture, abdominal or perianal fistulae) requiring no immunomodulator (IM), anti-TNF and no surgery. Mild UC was defined as no requirement for IM, anti-TNF and no colectomy. Results Four hundred and seventy-three CD and 189 UC were included (median follow-up: 13 and 11 years respectively). At 1 year, 147 patients had mild CD. At 5 years and the maximum follow-up, 56% and 13% patients still had mild CD, respectively. At 1 year, 142 patients had mild UC. At 5 years and the maximum follow-up, 72% and 44% still had a mild UC, respectively. Factors associated with long-term mild CD and UC were older age at diagnosis and absence of corticosteroids in the first year. In UC proctitis location was associated with mild UC. Conclusions In this cohort, 90% of CD patients and 3/4 of UC with mild disease at 1 year lost their mild disease status over time. An old age at diagnosis was predictive of the persistence of a mild CD and UC.
引用
收藏
页码:712 / 719
页数:8
相关论文
共 50 条
  • [21] Thioguanine in inflammatory bowel disease: Long-term efficacy and safety
    Ward, Mark G.
    Patel, Kamal V.
    Kariyawasam, Viraj C.
    Goel, Rishi
    Warner, Ben
    Elliott, Tim R.
    Blaker, Paul A.
    Irving, Peter M.
    Marinaki, Anthony M.
    Sanderson, Jeremy D.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2017, 5 (04) : 563 - 570
  • [22] Thymectomy in myasthenia gravis:: Long-term evolution and predictive factors
    Pérez-Nellar, J
    Negrín, A
    Llorens, JA
    Ferrá, A
    Pardo, A
    Parisi, N
    REVISTA DE NEUROLOGIA, 2000, 30 (09) : 801 - 806
  • [23] Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease
    Braga Neto, Manuel B.
    Gregory, Martin H.
    Ramos, Guilherme P.
    Bazerbachi, Fateh
    Bruining, David H.
    Abu Dayyeh, Barham K.
    Kushnir, Vladimir M.
    Raffals, Laura E.
    Ciorba, Matthew A.
    Loftus, Edward V., Jr.
    Deepak, Parakkal
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (07) : 1089 - 1097
  • [24] Patient assessment of the long-term benefits of surgery in inflammatory bowel disease
    Medina, C
    Vergara, M
    Casellas, F
    Naval, J
    Lara, F
    Malagelada, JR
    REVISTA CLINICA ESPANOLA, 2000, 200 (09): : 470 - 474
  • [25] Incidentally Diagnosed Inflammatory Bowel Disease: Prevalence and Long-Term Outcomes
    Bronze, S. M. Tubal
    Shenoy, S.
    Agrawal, M.
    Colombel, J. F.
    Rodriguez-Lago, I
    Ungaro, R. C.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I802 - I802
  • [26] Safety of long-term mesalamine therapy in patients with inflammatory bowel disease
    Schroeder, KW
    Tremaine, WJ
    Albrecht, HH
    VerstBrasch, CL
    Zorich, NL
    GASTROENTEROLOGY, 1996, 110 (04) : A1011 - A1011
  • [27] An update on the safety of long-term vedolizumab use in inflammatory bowel disease
    Honap, Sailish
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (09) : 767 - 776
  • [28] The Loneliness of Long-Term Thiopurine Monotherapy for Patients with Inflammatory Bowel Disease
    Robert N. Lopez
    Andrew S. Day
    Digestive Diseases and Sciences, 2021, 66 : 1390 - 1391
  • [29] Management and long-term outcome of severe acute inflammatory bowel disease
    Lehur, PA
    GuiberteauCanfrere, V
    LeBorgne, J
    SEMAINE DES HOPITAUX, 1997, 73 (13-14): : 409 - 416
  • [30] Prevalence and long-term effect of antiplatelet use in inflammatory bowel disease
    Mantaka, A.
    Renieri, V.
    Koutroubakis, I.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S249 - S250